• Fri news: Gilead withdraws bladder cancer drug. Amgen and Intercept PDUFA date pushback. CVS replaces CEO. Supernus depression trial. AbbVie Parkinson’s approval. See more on our front page

FDA approval for Gilead's HCV drug









AbbVie's combination of glecaprevir and pibrentasvir looks likely to gain approval as an eight-week regimen in all genotypes of hepatitis C and in patients who've never undergone treatment. Gilead's Harvoni is approved as an eight-week regimen, but only in one subset of patients. AbbVie will price its two-pill drug like its Viekira Pak, another hepatitis C combination that goes for about $28,000 per month. AbbVie will aggressively market the two-drug combo against Gilead's Harvoni and Epclusa, he said.
This strategy is likely to result in significant market share for AbbVie, given the convenience and excellent efficacy of their two-drug combination
 




AbbVie's combination of glecaprevir and pibrentasvir looks likely to gain approval as an eight-week regimen in all genotypes of hepatitis C and in patients who've never undergone treatment. Gilead's Harvoni is approved as an eight-week regimen, but only in one subset of patients. AbbVie will price its two-pill drug like its Viekira Pak, another hepatitis C combination that goes for about $28,000 per month. AbbVie will aggressively market the two-drug combo against Gilead's Harvoni and Epclusa, he said.
This strategy is likely to result in significant market share for AbbVie, given the convenience and excellent efficacy of their two-drug combination
Turn out the lights, the party's over. Not good folks, not good. Is Abv hiring?
 




Turn out the lights, the party's over. Not good folks, not good. Is Abv hiring?

I hope the Karma bitch bites everyone here hard, especially KD in the northeast....total douche. Everyone else with a hair across their ass that we were the only game in town deserves whatever comes along. Pompous shit heads